• Sorrento Receives Authorization From the UK Regulatory Agency to Conduct a Phase 2 Clinical Trial for COVI-DROPS in an Outpatient Setting

    1 month ago - By San Diego Biotechnology

    SAN DIEGO, June 11, 2021 - Sorrento Therapeutics, Inc. today announced that the Medicines and Healthcare products Regulatory Agency , the United Kingdom's regulatory agency, has cleared Sorrento's COVI-DROPS product candidate for a Phase 2 efficacy trial. The application was submitted as a rolling...
    Read more ...